We have developed a Regulatory briefing book in RTCure. This has informed our regulatory discussions, identifying key issues such as the identification of unmet need, well-defined criteria to identifying patients at risk, and care pathway analysis with information on costs of early intervention vs potential savings to the society would be required. This document was the basis of initial discussion with the Swedish Medical Products Agency. Read it here!
top of page
Search
Recent Posts
See AllCan the immune system be reset in transplantation and autoimmunity? A series of 4 reviews from the RTCure consortium is out and tells you...
Tom Esterine and Ruth Williams are two Expert Patients at King’s College London, who work with Heidi Lempp in the Centre for Rheumatic...
Following this link you can find the EULAR Patient Research Partners newsletter of May 2020. This newsletter contains an invitation to...
bottom of page
Comments